177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

Conclusion: 177Lu-lilotomab-satetraxetan has the potential to reverse rituximab resistance; it can increase rituximab binding and ADCC activity in vitro and can synergistically improve antitumor efficacy in vivo.

Source: Journal of Nuclear Medicine - September 30, 2020 Category: Nuclear Medicine Authors: Malenge, M. M., Patzke, S., Ree, A. H., Stokke, T., Ceuppens, P., Middleton, B., Dahle, J., Repetto-Llamazares, A. H. V. Tags: Basic Source Type: research